Team:Washington/Bibliography

From 2010.igem.org

(Difference between revisions)
Line 30: Line 30:
[[Image:CapDCP_MassSpecNoMethionine.png|thumb|780px|right| Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec]]
[[Image:CapDCP_MassSpecNoMethionine.png|thumb|780px|right| Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec]]
 +
=Using Recombineering to create a constitutive T6SS=
 +
[[Image:Washington Recombineering.jpg|400px|thumb|right|Insertion of T7 promoters]]
 +
The process for using homologous recombination to replace the T6SS native promoters is simple.  We begin with a previously characterised fosmid (a large, single-copy plasmid based on the F' plasmid) which contains all the genes in our T6SS.  Of particular interest is the ''fha1-tssA1'' intergenic region containing the promoters.  We transform this fosmid into recombineering strain ''E. coli'' SW102, which contains heat-inducible lambda phage recombinases and lacks the galactose metabolism gene ''galK''.
 +
Using PCR, we create a cassette containing the ''galK'' gene flanked by 50 bp of homology to the intergenic region.  The lambda recombinases integrate the cassette into the fosmid.  The transformants are plated on minimal galactose media to select for the recombinants.
 +
 +
A second cassette is created via PCR, this time containing our new promoters.  In this case, we chose to use T7 phage promoters due to their constitutive expression and small size, making them easier to synthesize.  The promoters are again flanked with homologous regions, and integrated into the fosmid.  This cassette displaces the ''galK'' cassette.  The transformants are this time plated on 2-deoxy-galactose (DOG), which is a toxic homolog to galactose.  Cells which can metabolize galactose (that is, those with a functioning ''galK'' gene) are killed, while those without the gene are unharmed.
 +
 +
The final step is to transform the recombinant plasmid into a T7 polymerase expression strain, to allow T6SS constitutive expression.
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->

Revision as of 23:47, 1 October 2010

Include references

Expected weight of CapD_CP without Methionine=55285Da, with Methionine=55417Da. Our mass spec detected a peak at 55274.8Da (no Methionine) well within the 0.02% error limit for our mass spec

Using Recombineering to create a constitutive T6SS

Insertion of T7 promoters

The process for using homologous recombination to replace the T6SS native promoters is simple. We begin with a previously characterised fosmid (a large, single-copy plasmid based on the F' plasmid) which contains all the genes in our T6SS. Of particular interest is the fha1-tssA1 intergenic region containing the promoters. We transform this fosmid into recombineering strain E. coli SW102, which contains heat-inducible lambda phage recombinases and lacks the galactose metabolism gene galK.

Using PCR, we create a cassette containing the galK gene flanked by 50 bp of homology to the intergenic region. The lambda recombinases integrate the cassette into the fosmid. The transformants are plated on minimal galactose media to select for the recombinants.

A second cassette is created via PCR, this time containing our new promoters. In this case, we chose to use T7 phage promoters due to their constitutive expression and small size, making them easier to synthesize. The promoters are again flanked with homologous regions, and integrated into the fosmid. This cassette displaces the galK cassette. The transformants are this time plated on 2-deoxy-galactose (DOG), which is a toxic homolog to galactose. Cells which can metabolize galactose (that is, those with a functioning galK gene) are killed, while those without the gene are unharmed.

The final step is to transform the recombinant plasmid into a T7 polymerase expression strain, to allow T6SS constitutive expression.

Accomplishments and Submitted Parts